LexaGene sells MiQLab diagnostic testing system to Alpine Veterinary Hospital in California

LexaGene Holdings Inc (OTCQB:LXXGF) (CVE:LXG) (FRA:5XS2), a molecular diagnostics company, has sold a MiQLab diagnostic testing system to Alpine Veterinary Hospital in Concord, California.  “We are excited that Alpine Veterinary Hospital sees that the future of animal care begins with the MiQLab System,” CEO Dr Jack Regan said in a statement. “We continue to gain momentum in veterinary health as we’ve generated multiple MiQLab sale leads from ACVIM Forum, which we attended last week, and from the hard work of our dedicated sales team.”  MiQLab delivers excellent sensitivity, specificity, and breadth of detection. It can test for 27 pathogens and returns results in about one hour versus 1-3 days at a lab.  READ: LexaGene says Denver Animal Emergency buys MiQLab diagnostic testing system In addition, the company announced that Dr Regan will be presenting at three upcoming conferences: the first is investor-focused, the second is about advancements in microfluidics, and the third is about bio-threat detection.  On June 14 (today), he will speak at Lytham Partners Summer 2021 Investor Conference. An audio webcast of the presentation will be made available on LexaGene’s website and its management will also participate in one-on-one meetings throughout the event, which runs until June 16. To arrange a meeting, please contact a Lytham Partners representative at 1x1@lythampartners.com or register at http://www.lythampartners.com/summer2021invreg. On June 15, Dr Regan will present as part of the ‘Microfluidic Hotseat’ at the Annual Microfluids Consortium, hosted by the Centre for Business Innovation, a collaboration managing a portfolio around specific areas of business process and technology, where members share information to pursue like-minded business and innovation goals. The title of his talk is "Sample-to-Answer Pathogen Detection using Flow-Through Sample Preparation and Customized Multiplex PCR." Members will have the opportunity to meet microfluidics-enabled startups, such as LexaGene, whose pathogen detection system offers rapid molecular testing at the point of need in multiple market verticals. Registration is still available for those wanting to watch the presentation. Lastly, on June 17, Dr Regan will be a featured speaker at the 28th International Biothreat and Pathogen Detection Conference. His presentation, "Rapidly Configurable Automate Multiplexed Pathogen Detection System for Novel Threat Detection," will focus on the ability of the MiQLab to be easily configured to detect multiple pathogens in a single sample as a critical measure in biosurveillance activities. Examples of MiQLab’s applications for biothreat surveillance and diagnostics will be featured.  Registration is still available for those wanting to watch the presentation. LexaGene said it anticipates issuing a news statement on the day of the conference to disclose any data to be presented. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham